Skip to main content

Infectious Disease Diagnostics Market Worth USD 19.35 Billion – Current Status, Statistics, Growth Dynamics And Future Trends

 What This Report Will Provide?

HPV diagnostics market also formed one of the major market segment in infectious disease diagnostics market. HPV infections can be prevented, if diagnosed in the early stages. Pap tests are the most preferred tests to detect cervical cancer. Rapid HPV diagnostics and real-time PCR are the most advanced methods which have 95% sensitivity to HPV and cover a broad range of

Revenue Growth:

[170 Pages Report]The global infectious disease diagnostics market was valued at USD 13.93 Billion in 2016 and projected to reach USD 19.35 Billion in 2022, at a CAGR of 5.6%.



Major Growth Boosters:

Growth in this market is primarily driven by the increasing global prevalence of infectious diseases, shift in focus from centralized laboratories to decentralized point-of-care testing, and growth in funding for research on infectious disease diagnostics.

Download PDF Brochure:   https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589 

Growth in the influenza market can be attributed to the rising prevalence of influenza, growth in research funding for influenza diagnostics, and rising demand for faster diagnosis and control of influenza. Advancements in technologies such as PCR and proteomics and significant growth prospects in developing countries are also expected to offer growth opportunities for players in the influenza diagnostics market

Critical questions the report answers:

  • Where will all these developments take the industry in the long term?
  • What are the upcoming trends for the infectious disease diagnostics market?
  • Which segment provides the most opportunity for growth?
  • Who are the leading vendors operating in this market?
  • What are the opportunities for new market entrants?

Request Sample Report:   https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589 

By product and service, assays, kits and reagents segment to record the highest CAGR during the forecast period

Increased accessibility and the increasing number of IDD tests conducted are the key drivers for this segment. Globally, the volume of IDD tests is increasing mainly due to the rising geriatric population; increasing prevalence of infectious diseases; increased variety of reagents available and analytical techniques employed; and the continuous launch of newer, faster, and more reliable products.

Regional Growth Analysis:

The global healthcare consulting services market was dominated by North America, followed by Europe in 2017. Factors such as increasing M&A activity, pricing pressure on pharmaceutical companies are driving the growth of the healthcare consulting services market in this region. Asia Pacific, however, is estimated to register the highest CAGR during the forecast period due to the increasing need for remote care and telemedicine in rural areas in the region.

Labels:

Comments

Post a Comment

Popular posts from this blog

Healthcare BPO Market To Reach $312.43 Billion By 2022 : Increasing Consolidation In The Healthcare Industry

  What This Report Will Provide? In the current market scenario, there is a growing demand for healthcare BPO services. The objective of this report is to define, describe, and forecast the market on the basis of outsourcing services including payer, provider, and pharmaceutical services and region. It provides detailed information regarding the major factors influencing the growth of healthcare outsourcing market. This report also tracks and analyzes competitive developments of the key players in terms of market developments, product portfolios, and financials. Expected Revenue Growth: Healthcare BPO market  is estimated to grow at a CAGR of 10.2% from 2017 to 2022 to reach $312.43 billion by 2022 from $191.68 billion in 2017. The base year considered for the study is 2016, and the forecast for the market size is provided for the period between 2017 and 2022. Major Growth Boosters: Patent cliffs, complex clinical trial protocols, and new reporting requirements are forcing pha...
Post a Comment
Read more

Autoinjectors Market | Newest Industry Data, Future Trends and Forecast 2023

Autoinjectors are used to self-administer drugs for the treatment of various diseases and conditions, such as rheumatoid arthritis, multiple sclerosis, diabetes, and anaphylaxis. Autoinjectors are easy to use, portable, and improve dosing accuracy, making them one of the most popular methods for the self-administration of drugs. The  global autoinjectors market  is projected to reach USD 85.31 billion by 2023 from an estimated USD 28.91 billion in 2018, at a CAGR of 24.2% during the forecast period (2018-2023). In terms of Therapy, the global autoinjectors market can be segmented into: Rheumatoid Arthritis Multiple Sclerosis Diabetes Anaphylaxis Other Therapies (Cardiovascular Diseases, Migraines, Psoriasis, and Anemia) By therapy, the rheumatoid arthritis segment is expected to account for the largest share of the market in 2018 On the basis of therapy, the autoinjectors market is segmented into rheumatoid arthritis, multiple sclerosis, diabetes, anaphylaxis, and other therap...
Post a Comment
Read more

North American Nuclear Medicine Market To Reach USD 2.7 Billion By 2024 – Expansion In Emerging Economies

  What This Report Will Provide? The study involved four major activities in estimating the current size for the North American nuclear medicine market. Exhaustive secondary research was done to collect information on the market and its different subsegments. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Expected Revenue Growth: [159 Pages Report] The  North American nuclear medicine market  is expected to reach USD 2.7 billion by 2024 from an estimated USD 2.2 billion in 2019, growing at a CAGR of 4.1% during the forecast period. Major Growth Boosters: Growth in the market can primarily be attributed to factors such as the increasing incidence and prevalence of cancer & cardiac ailments and initiatives to lessen the demand-supply gap of Mo-99. However, the short half-life of radiopharmaceuticals reduces their potential adoption, while hospital budget cuts and high equipment...
Post a Comment
Read more